A
Abdominal pain 290
Acceleration index 681
Acetylcholine 335
Acid derivative 98
Acromegaly 89
Activated nicotinamide adenine dinucleotide phosphate oxidase 771
Acute coronary syndrome 11–13, 26, 32, 44, 45, 54, 74, 103, 115, 117, 144, 238, 282, 317, 320, 321, 323, 324, 328, 329, 332, 333, 342, 344f, 347, 349, 361, 368, 420, 430, 431, 450, 452, 497, 538, 548, 592, 699, 610, 735–737, 794, 795, 802, 842, 855, 857, 858, 867, 869, 873, 884, 887, 887t, 910
development of 317
history of 534
pathogenesis of 321
secondary prevention of 318
Acyl-coenzyme A cholesterol acyltransferase inhibitors 751
Ad hoc analysis 364
Adaptive intimal thickening 582
Adenine dinucleotide phosphate 317
Adjunct nonstatin therapy 735
Adult treatment panel 45
Aerobic exercises 83
Airway epithelium, structural hallmark of 786
Airway smooth muscle proliferation 786
Alanine transaminase 285
Albumin 21
Alipogene tiparvovec 252
Alpha-linolenic acid 707
Alveolar epithelial cells 788
Alzheimer's dementia 716
Amino acids 89
Aminotransferase elevation, risk of 157
Amlodipine monotherapy 399
Ampulla cardiomyopathy 378
Anacetrapib 255
Androgen excess, signs of 204
Angiography 594
Angiopoietin-1 133
Angiotensins 135
ANKDD1A gene 245
Anorexia nervosa 86
Anthocyanins 357
Antiarrhythmic drugs 433
Antiatherogenic agents 333
Antiatherosclerotic vascular protection 453
Anticoagulant therapy 465
Antidepressant effects 154
Antihyperlipidemic therapy 209
Antihypertensive medications 386
Antihypertensive treatment 400
Anti-inflammatory actions 421
Anti-inflammatory molecule 257
Anti-inflammatory pleiotropic effects 93
Antiplatelet 465
Anti-proprotein convertase subtilsinkexin 9 monoclonal antibodies 875t
Antipsychotics 89
Antithrombotic agents 343
Aortic arch 667f
Aortic arterial stiffness 448
Aortic atheromatous plaques 447
Aortic transcatheter valve, placement of 457
Aortic vessel wall thickness 672
Apheresis 301
Apical ballooning cardiomyopathy 378
Apo E gene 337
A 68
AI 303
ratios 78
containing lipoproteins 94
gene 328
measurements of 18
B-100 14
E 243
levels of 129
Apoprotein 330
Apoptotic pathways 494
Arcus corneae 85
Arrhythmogenesis, suppression of 420
Arterial diameter change 595
Arterial distensibility 595
Arterial fibrillation 402
Arterial revascularization 842
Arterial strain 595
Arteriogenesis 494
Arteriosclerotic cardiovascular disease 736
Arthralgias 850
ASNSD1 gene 245
Astrocytes 465
Atherogenic lipids 116
Atherosclerosis 25, 50, 54, 81, 85, 91, 93, 137, 138, 139fc, 144, 146, 184, 196, 225, 259, 266, 279, 334, 361, 393, 404, 422, 447, 448fc, 452, 493, 496, 510, 581, 583, 591, 599, 610, 612, 657, 670, 671, 674, 699, 700f, 702
cardiovascular disease 25
cause of 351
conventional imaging of 701
disease progression 65
in young diabetes 510
marker of subclinical 582
pathology of 657
process 593
trials 856
statin-induced regression of 588
stress-induced 138
Atherosclerotic areas 481
Atherosclerotic cardiovascular disease 4, 9, 21, 30, 37t, 39, 46, 61, 76, 81, 94, 115, 126, 194, 204, 218, 237, 247, 251, 257, 272, 282, 293, 296, 303, 312, 332, 353, 367, 385, 390, 402, 450, 473, 510, 517, 533, 538, 548, 566, 597, 606, 622, 657, 707, 734, 752, 758, 793, 802, 840, 859, 866, 873, 875, 884, 886t, 887, 891, 900, 905, 912
progression of 452
risk categories for 333t
risk factor for 18
treatment of 194
Atherosclerotic coronary artery disease 329
Atherosclerotic formation 486
Atherosclerotic heart disease 418
Atherosclerotic peripheral vascular disease 493
imaging 693
inflammation 694f
instability 399
regression, statin-induced 591
stability 183
stabilization of 65
statin effect on 275
strategy of 701
unstable 342
visualization of 276
Atherosclerotic progression 376
Atherosclerotic risk 871
Atherothrombosis 494
Atherothrombotic events, prevention of 330
Atherothrombotic strokes 466
Atorva 44
Atorvastatin 11, 39, 44, 56, 72, 97, 105, 108, 115, 123, 128, 130, 144, 153f, 158, 165, 170, 187, 202, 205t, 207, 214, 220, 236, 247, 262, 269, 283, 318, 325, 330, 343, 349, 375, 398, 405, 434, 438, 459, 475, 487, 524, 529, 538, 562, 567, 570, 584, 591, 652, 737, 759, 793, 794t, 796, 812, 835, 858
combination therapy 286
comparative cholesterol efficacy 243
efficacy of high-dose 349
meta-analysis of 795t
role of 795
therapy 185
treatment 619f
trials 793
use of 419
ATP-binding cassette 718
Atrial samples, right 192
Attitudes 140
Autocrine functions 194
Autonomic nervous system 135
Autosomal dominant hypercholesterolemia 882
Autosomal recessive disorder 337
Axial sodium fluoride 696f
Azole antifungals 812
B
B cells, activated 180
B lymphocytes 93
Back pain 849
Bacteremia 821
Bacterium 787
Ballooning 156
Barbiturates 567
Bempedoic acid 41, 57, 69, 215, 252, 307, 308, 352, 353, 583, 850, 848, 851, 862, 863, 878, 880, 891, 892f, 894, 897, 911, 912
adverse events of 850
indications of 252
mechanism of action of 892f
pharmacokinetics of 878
side effects of 850b
Bempedoic drug trials 912t
Berberine 357
Berberol 357
Best medical therapy 599
Beta-adrenergic blocking agents 89
Biallelic mutations 252
Bioprosthetic valve degeneration 232
Black blood 671
Bloating 749
Blocking synthesis 363
Blood-brain barrier 466
Breastfeeding 803
Breath, shortness of 420
Broken heart syndrome 378
Bronchial asthma 140
Budesonide 220
Burns 89
Bypass surgery 141
C
C receptor gene 337
Calcineurin inhibitors 565
Capillary basal membrane 473
Carboxylation 192
Cardiac amyloidosis 648f
Cardiac arrest, resuscitated 268
Cardiac complication 458
Cardiac diastolic function 716
Cardiac illness 429
Cardiac muscle, lesions of 132
Cardiac myocytes 429
Cardiac resynchronization therapy 441
Cardiac transplant 875
Cardiac valves 456
Cardiomyocytes 378
Cardio-oncology, statin in 831
Cardiothoracic surgeries 820
Cardiovascular disease 16, 25, 38, 57, 65, 76, 81, 97, 102, 108, 115, 135, 144, 149, 164, 175, 219, 224, 239, 262, 266, 271, 281, 289, 293, 299, 303, 311, 312t, 325, 351, 361, 367, 391, 400, 404, 408, 433, 450, 516, 527, 542, 553, 565, 569, 581, 635, 642, 691, 707, 734, 753, 759, 801, 804, 848, 860, 869, 891, 900, 918, 919
development of 753
high-dose statins in 102
low-dose statins in 102
predictors of 179
premature atherosclerotic 299
primary 767
prevention of 539t
role in 711
secondary 767
sign of 146
statin
for primary prevention of 108
for tertiary prevention of 114
reduce 488
Cardiovascular disorders 133
Cardiovascular drugs 242
Cardiovascular effects 561
risk of 82
Cardiovascular heart disease 408
Cardiovascular outcome trials 902
Cardiovascular system 169
Carotenes 727
Carotenoids 719
atheroma 483
atherosclerotic disease 486
B-mode ultrasound of 588
distal common 589f
intima, higher 510
intimal-medial thickness 588
surgery 233
ultrasound of 657
Carotid atherosclerosis 661
Carotid disease, asymptomatic 599
Carotid interventions 599
Carotid revascularization 469
Carotid surgery trial, asymptomatic 599
Carotid ultrasound imaging 598
Catalase 190
Catalyzes intracellular esterification 751
Catecholamines 136
Causing thrombosis 317
Cavernosal artery 685f
Cavernosal endothelial dysfunction 153
Cell
adhesion 770
control 770
division autoantigen 1 574
functions 456
maintenance 257
part of 85
migration 132
Cellular adhesion molecules 487
Cellular development 770
Cellular mediators 194
Cellular redox signalling, disruption of 190
Cellular respiration 203
Central obesity 86
Cephalin 722
Cerebral amyloid angiopathy 834
Cerebral arterioles 465
Cerebral ischemia 470
Cerebral small vessel disease 465
Chanarin-Dorfman syndrome 780
Charlson comorbidity index 321
Cheaper drugs 63
Chemoattractant proteins 810
Chemokines 452
CHI3L2 gene 245
Cholangitis 172
Cholecystectomy 172
Cholecystitis 172
Cholecystokinin 86
Cholestasis 86
Cholesterol 18, 50, 54, 61, 81, 85, 91, 97, 104, 172, 174, 175, 228, 230, 236, 257, 262, 303–305, 307, 405, 433, 493, 557, 561, 571, 584, 683, 723, 727, 809, 920
confusion 227
coronary connection 227
de novo synthesis of 152
designs 91
efflux capacity 891
forming atheromas 684f
gallstones 172
hypothesis 228
in ischemia 343
intake 82
lipids including 85
modifying therapies 303
molecule 733
paradox 119
rich lipoprotein 289
stones 172
synthesis of 333
inhibition of 184f
Cholesteryl acid 544
Choroidal neovascularization 771
Chronic degenerative diseases, etiology of 138
Chylomicronemia syndrome 290
Chyme 86
Cimetidine 812
Ciprofloxacin 812
Clear serenity trial 850
Clear tranquility trial 850
Clofibrate 385
Clonidine 713
Clopidogrel 652
Cochlea 208
Cognitive dysfunction 516
Cognitive symptoms 212
Cohort whereupon therapeutics require 340
Colchicine, low-dose 453
Colesevelam 749
Colestipol 749
Collagen 185
Colon cancer cells 718
Community health centers 63
Concomitant statin therapy 163
Constipation 749
Content and description 184
Contraception 38
Contraction strain values 647
Copenhagen 53
Cornea 774
Corneal wound healing 768
Cornerstone therapy 447
CORONA trial 636
Coronary aneurysms 752
Coronary angiographic studies 613
Coronary angioplasty 141
Coronary arteriography 276
measurement 110
Coronary artery disease 12, 13, 25, 26, 50, 53, 85, 114, 119, 128, 132, 135, 156, 163, 194, 208, 232, 261, 266, 275, 279, 299, 309, 329, 332, 364, 367, 378, 402, 405, 415, 418, 431, 433, 436, 437, 447, 450, 457, 494, 505, 537, 599, 606, 639, 642, 654, 691, 757, 793, 795, 801, 857, 858, 860, 867, 869, 875, 882, 911
chronic 333
contraindications 801
high risk for 422
indications 801
malignant 187
management of 648
prevalence of 15
prevention of 66
Coronary bypass surgery 282
Coronary calcification 610
Coronary circulation 329
Coronary heart disease 25, 36, 48, 74, 98, 102, 108, 115, 126, 137, 149, 165, 225, 261, 290, 303, 309, 328, 333, 347, 363, 368, 375, 392, 416, 459, 473, 505, 512, 542, 571, 582, 597, 691, 716, 752, 759, 827, 868, 879, 904
cause of 91
primary prevention of 303
Coronary intravascular ultrasound 875
Coronary organic stenosis 335
Coronary plaques 275
Coronavirus disease crisis 815
Corpus cavernosum 152
Corticosteroids, doses of 169
Cotrimoxazole 567
Cough 849
C-reactive protein 19, 26, 32, 65, 66, 73, 76, 93, 97, 111, 147, 153, 164, 167, 178, 179, 191, 204, 218, 219, 236t, 239, 275, 280, 304, 311, 320, 323, 334, 344, 348, 368, 406, 429, 434, 466, 545, 810, 810f, 839
decreasing 520
high 856
role of 321f
Crystalline cholesterols 303
Curcuminoids 357
Cushing's disease 170
Cyclophosphamide 567
CYFI P2 gene 245
Cytomegalovirus infection 875
Cytoskeletal organization 770
Cytosolic multiprotein 452
d
Dalcetrapib 255
Danazol 739
De novo lipogenesis 707
Dehydroepiandrosterone sulfates 206
Dextran sulfate cellulose adsorption 16
Diabetes 18, 52, 57, 62, 82, 85, 86, 96, 111, 126, 140, 144, 150, 164, 174, 178, 184, 202, 263, 268, 269, 283, 290, 308, 317, 324, 361, 391, 405, 419, 473, 476, 481, 494, 509, 518, 527, 594, 716
affects 473
and statin use 219
control and complications trial 574
dangerous liaison of 476
diagnosed 285
group, risk factors in 474t
hypertension 447
increased risk of 547
insulin-dependent type 1 96
lipid abnormalities, type 2 82
non-insulin-dependent 539
with obesity 542
Diabetes mellitus 6, 13, 27, 38, 61, 72, 89, 99, 102, 143, 149, 187, 219, 230, 237, 273, 289, 298, 312, 321, 334, 353, 364, 369, 400, 406, 447, 527, 534, 538, 542, 575, 622, 734, 757, 794, 828, 842, 844, 869, 888, 910
causes 527
resolution 920
risk enhancers in 6b
new-onset 350
statin-induced new-onset 272
type 2 11, 21, 31, 67, 74, 79, 81, 94, 96, 109, 129, 152, 164, 257, 259, 263, 297, 320, 361, 369, 408, 509, 515, 517, 520, 527, 542, 554, 794, 874, 888
poorly controlled 290
Diabetic cardiomyopathy 646f
Diabetic kidney 573
Diabetic macular edema, proliferative retinopathy of 772
Diabetic patients 130
Diabetic stroke 474
Dialysis 110
Diazoxide 713
Dietary carotenoids 719
Dietary restriction 747
Dietary triacylglycerols 722
Diet-heart hypothesis 227
Dihomo-gamma-linolenic acid 727
Dimethylarginine dimethylaminohydrolase 180
Direct antioxidant mechanisms 809
Disability-adjusted life years 474
Diuretics 86
Doppler evaluation 681
Doppler study 627
Double filtration plasmapheresis 16
Downstream luminal pressure 494
DTD1 gene 245
Duodenum 86
Dysbetalipoproteinemia 779
Dysfunctional endothelium 320
Dysglycemia 528
Dyslipidemia 10, 18, 25, 33fc, 40, 81, 85, 96, 118, 122, 135, 139, 139fc, 144, 150, 164, 165fc, 169, 170f, 174, 178, 200, 208, 220, 233, 247, 261, 289, 305, 321, 347, 361, 378, 397, 404, 409, 430, 452, 468, 473, 481, 493, 509, 528, 542, 561, 573, 654, 660, 686, 699, 701t, 705, 715, 752, 781, 827, 859, 866, 871, 882, 891, 900, 905, 919
and add-on therapy 364
causes of 85
clinical 289
control 509
diagnosis of 290
during pregnancy, management of 175
etiopathogenesis of 262
genesis of 543
in pregnancy 174
inflicted stroke 833
guidelines for 297
pathogenesis of 543f
pathophysiological mechanism of 169
plausible role of 379
postrenal transplant 565
primary 81
resolution 920
risk of 83
role of 562
screening for 752
spectrum of 527
stress-induced 135
triggered atherosclerotic cardiovascular diseases 882
types of 85
Dyslipoproteinemia 528
Dyspepsia 253
Dyspnea 85
Dysrhythmia 921
E
Early statin treatment 592
Ebola virus disease 816
Echogenic plaque 659f
Elastic modulus 595
Elderly diabetics 515
Elderly hypertensives, cardiovascular risk in 404
Elective perioperative mortality 459
Elevated cholesterol, management of 539
Elevated triglycerides, treatment of 293fc
Emerging drugs 56
Emotions 140
End-expiratory pressure ventilation, positive 820
Endothelial damage 493
Endothelial dysfunction 147, 152, 153, 184, 194, 197f, 279, 317, 401, 406, 419, 447, 450, 473, 528, 684, 686, 816
and inflammation 537
reduction of 235
statin improve 147
Endothelial injury 482
Endothelial lipase 340
activity 640
Endothelial surface 345
Endothelial-leukocyte interactions 93
Endothelin-1, expression of 772
Endovascular stent 459
End-systolic volume 643
Energetic fuels, mobilization of 135
Enterocytes 244
Enzymatic system 203
Eosinophilia, drug rash with 781
Eosinophils 786
Epicardial arteries 332
Epicardial coronary arteries 275
Epigastric approach 681f
Episcleritis 769
Epithelial cell injury 786
Erectile and gonadal functions 153
Erectile endothelial functions 154
Ethyl eicosapentaenoic acid 292
Euthyroid person 162
Excessive oxidation, role of 317
Exogenous lipoprotein pathway 86
External elastic membrane volume 277
Extracellular matrix deposition 184
Extracellular superoxide dismutase 192
Extrahepatic sites 128
Extraocular muscle 769
Ezetimibe 3, 10, 28, 30, 40, 46, 68, 77, 77t, 79, 93, 97, 167, 187, 215, 240, 282, 286, 291, 294, 339, 347, 351, 353, 368, 437, 438, 448, 451, 469, 475, 497, 529, 538, 544, 583, 608, 739, 749, 861, 862, 897f
administration 78
association 78t
combination 76
dosage of 79
effect of 451
on atherosclerosis, effects of 451
pharmacological characteristics of 76
plus simvastatin 368
role of 544
tolerability of 79
F
Familial heterozygous hypercholesterolemia 54
Familial homozygous hypercholesterolemia 54
Familial hypercholesterolemia 11, 13–16, 31, 51, 57, 61, 67, 99, 114, 200, 237, 243, 266, 289, 300, 307, 324, 329, 330, 337, 352, 364, 369, 436, 512, 549, 749, 752, 757, 759, 840, 859, 861, 864, 874, 884, 888, 900
causes of 86f
cholesterol burden in 339f
diagnosis of 860
evidence of 513
heterogeneity of 15
screening of 859
therapies for 750
treatment of 757
Familial hyperchylomicronemia 779
Familial hypoalphalipoproteinemia 290
Familial lipoprotein lipase deficiency 779
Family meals 748
Fatal stroke, risk of 285
Fatty deposits 82
Fatty liver 158
Fentanyl 812
Fibric acids 749
Fibrillation 708
Fibrinogen 179
Fibroatheroma 118
Fibroblast growth factor 133
Fibrous core 672
Fibrous plaque 277
Fish oils 497
Flaccid 684
Flank approach 681f
Flavonoids 240
Flow-mediated dilatation 563
Fluvastatin 39, 44, 72, 105, 108, 123, 128, 157, 173, 185, 187, 236, 242, 261, 279, 318, 335, 375, 398, 405, 434, 459, 475, 520, 538, 562, 565, 567, 570, 759, 835
extended-release 759
Fly-buy renal angiography 505
Focal segmental glomerulosclerosis 562
Follicle-stimulating hormone 206
Fourier trial 27
Framingham heart 473
Framingham offspring study 557
Free cholesterol 751
G
G protein-coupled chemokine receptor-7 701
Gallbladder stones 172
Gamma interferon 320
Gamma-aminobutyric acid 717
Ganglionopathy 153
Gastrointestinal side effects 292
Gastrointestinal symptoms 749
Gastrointestinal tract 167
GATM gene 245
Gebrochenes-Herz syndrome 378
Gender and cardiovascular risk 262
Genetic confirmation, prevalence of 329
Genetic considerations 436
Genetic defect 338
Genetic dyslipidemia, signs of 10
Genetic hyperlipidemias 54
Genetic predisposition 494
Genetic susceptibility factors 227
Genome, advances in 245
Genomic ribonucleic acid 816
Genotypic components 337
Ghrelin 137
Global database analysis 915
Glucosamine 357
Glucuronosyltransferases 127
GLUL gene 245
Glutathione-S-transferase 190
Glycated lipoprotein 299
Glycation enhances 299
Glycemia 363
Glycoprotein synthesis 333
Goal-directed medical therapy 233
Gonadotropins 135
Gout 850
Graves’ disease 163
Grayscale median 660
GSDME gene 245
Guinea pig 209
H
Haloperidol 812
Haptoglobin 179
Harmacogenetics implementation consortium 245
Health paradox 726
Healthy diets 56
Healthy human volunteers 310
Healthy protein sources 3
epidemiology 208
etiology of 208
in vitro 209
incidence of 208
noise-induced 209
pathophysiology of 208
progress of 209
statin in 208
treatment 208
of sensorineural 209
Heart failure 67, 75, 104, 149, 163, 202, 218, 267, 283, 334, 378, 402, 405, 415, 418, 421, 431, 441, 442, 453, 547, 635, 654, 795, 802, 857, 919
acute 422
device therapy in 441
history of 282
nonfatal 626
prevention 422fc
severe 470
with coronary artery disease 422
with preserved ejection fraction 443
without atherosclerosis 421
Heat shock proteins, control of 334
Helsinki heart study 742
Hematopoiesis 179
Hemodynamic shear stress 343
Hemoglobin, glycosylated 308
Heparin mimetics 876
Hepatic cholesterol synthesis 65
Hepatic decompensation, prevention of 159
Hepatic dysfunction, severe 351
Hepatic exposure 242
Hepatic expression 759
Hepatic fibrosis 168
Hepatic hydroxymethylglutaryl coenzyme A 562
Hepatic lipase 244
Hepatic metabolism 439
Hepatic stellate cell 220
Hepatic synthesis 363
Hepatic toxicity 298
Hepatocellular carcinoma 168
Hepatocellular injury 157
Heterozygous 14
High-efficiency particulate air 333
plus ezetimibe 49
High-intensity trials 858t
Histamine 785
Histidine decarboxylase 785
Hormonal changes, statin-induced 153
Hounsfield scale 887
Human aortic endothelial cells 179
Human inflammation 235
Human organs, functioning of 91
Human umbilical vein endothelial cells 179
Hydralazine 713
Hydrolysis 725
Hydrophobicity 242
Hydroxy methylglutaryl coenzyme A 583
Hydroxy β-methylglutaryl-coenzyme A 133
Hydroxychloroquine 524
Hydroxytyrosol acid 727
Hypercholesteremia 143
Hypercholesterolemia 77, 78, 93, 128, 132, 175, 183, 184, 190, 195, 244, 273, 328, 329, 378, 379, 397, 399–402, 406, 436, 581, 594, 683, 740, 750, 809, 911
family history of 329
high risk of primary 126
treatment of 333
Hyperchylomicronemia 779
Hypercortisolism, correction of 170
Hyperintense 672
Hyperkalemia 356
Hyperlipidemia 18, 51, 54, 81, 138, 158, 170, 176, 208, 209, 209t, 220, 230, 262, 290, 305, 317, 320, 335, 338, 379, 390, 419, 422, 564, 575, 684, 749t
causes of secondary 86b
classification of 50
control
primary prevention of 236
secondary prevention of 236
diagnosis of 162
cornerstone of 56
primary 85
secondary 85
treatment of 56
Hypertension 18, 38, 81, 93, 99, 126, 139, 140, 143, 150, 170f, 202, 282, 291, 308, 317, 321, 385, 388, 397, 400, 401, 401t, 418, 419, 473, 481494, 522, 542, 553, 581, 594, 622, 712, 717, 780, 833, 849, 920
absence of 391
classification of 402t
cumulative incidence of 403f
early-onset 404
elderly with 390
global burden of 397
increases 405
isolated systolic 399
management of 409
nonpharmacological therapy of 828
presence of 391
resolution 920
role of 262
statin in 397
types of 404
with cardiovascular diseases 404f
Hyperthyroidism 162
drug interactions in 163
lipids in 162
modification in 163
statin therapy in 163
treatment of 162
Hypertrophy 638
Hyperuricemia 850
Hypoglycemic agents 545
Hypointense 672
Hypolipidemic disorders, group of 338
Hypolipidemic drugs 175
Hypolipidemic therapy 322
Hypotensive action, mechanisms of 398
Hypoxia 699
I
Idiosyncratic reactions 124
IGTB3 gene 245
Ileal bypass surgery 202
Immunosuppressive drugs, effects of 233
Implantable cardiac devices 441
Inclisiran 41, 48, 69, 307, 308, 340, 352, 353, 363, 364, 368, 848, 862, 863, 875, 878, 880, 894, 897, 897f, 903t, 904, 907, 909
advantages of 907
dosage 875
drug trials 910t
effect of 48f
pharmacodynamics of 875
phase-3 trials with 903t
recent trials of 900
safety of 895
side effects of 849b
therapeutic status of 880
therapy 891
use of 880
with statins 896
and effect 363
Indinavir 812
Infectious diseases, use of statins in 816
Inflammasome 452
Inflammatory agent 524
infiltration, decrease 180
number of 195
peribronchial infiltration of 787
perivascular infiltration of 787
Inflammatory eye disease, statin in 774
Inflammatory mediators, secretion of 275
Inflammatory molecule, decrease in 345
Inflammatory response, moderate 146
Inflammatory serum markers 810
Inflammatory states, acute 429
Inflammatory syndrome 809
Infrainguinal bypass surgery 305
Inhibit cancer-cell proliferation 716
Inhibiting monoclonal antibodies 749
Initiating tissue inflammation 456
Insights 91
Intense lipid-lowering therapy, evidence for 144
Intensity hydrophilic statins 157
Intensity lipophilic statins 157
Intensity regimens, statin dose for 387t
Intensity rosuvastatin 304
Intensive cholesterol-lowering therapy 584
Intensive lipid-lowering therapy 334
Intensive rosuvastatin therapy 344
Intestinal cholesterol absorption 67
Intestinal microbiota 555
Intestine 459
Intracellular calcium ions 378
Intracellular tetrahydrobiopterin 191
Invasive mechanical ventilation 821
Irbesartan 812
Ischemic cardiovascular disease 585
Ischemic cerebrovascular accidents, history of 102
Ischemic disease 539
Ischemic nephropathy, progressive 505
Isoenzymes 349
Isoflavones 357
Isomerization 725
Isoniazide 567
Isoprenylation, inhibition of 556
Isotretinoin 83
Isovolumic relaxation phase, strain rate during 627
K
Kawasaki disease 752
L
Lacunar infarct 474
Lacunar strokes 465
Landmark trials and research 570
L-carnitine 203
Left atrium strain 654
Left ventricular dysfunction 453
Left ventricular epicardium 643f
Left ventricular mass 639
Lenticulostriate 465
Leptin, regulation of 555
Lescol renal transplantation, assessment of 565
Lesions, development of 179
Lethal ventricular arrhythmias 433
Leukoaraiosis 474
Lichen planus 780
Lidocaine 567
Life-threatening arrhythmias 441
Linolenic omega-3 728
Lipemia retinalis 290
accumulation 670
analyses 312t
association 324
buildup 699
core 672
effects on 438
goals 102
imbalance of 311
in myocardium, mechanisms of action of 629fc
low-density 683
mild elevations of 85
nephrotoxicity hypothesis 562
on myocardium, adverse effects of 378
pathways 87f
peroxidation 192
pool 614
statin effect on 73
targets 748
arm 737
armamentarium 862t
efficacy 247
implementations of 61
medications 498
nutraceuticals 216
regimen 16
stable 16
targets in 30
Lipidosis, direct 209
Lipid-rich core, fibrous cap of 275
Lipodystrophy 89
Lipogenesis 169
Lipolysis 169
Lipoprotein 18, 37, 50, 53, 54, 57, 69, 86, 89, 162, 225, 247, 299–301, 312, 330, 367, 438, 450, 451, 494, 494t, 512, 724, 735, 750, 753t, 839, 887
abnormalities 96
cholesterol, high density 542
classes 724f
concentration of 69
containing 247
triglycerides 493
effect on 734
inhibitor of 309
like metformin 545
metabolism 718
disorders of 859
modification 96
plasma levels of 448
L-nitro arginine methyl ester 195
Local arterial stiffness, evaluation of 595
Local hemodynamics 275
Lopinavir 812
Losartan 812
Lovastatin 39, 44, 65, 72, 73, 105, 108, 123, 128, 157, 163, 170, 173, 185, 187, 229, 240, 242, 261, 262, 304, 375, 405, 434, 459, 475, 520, 529, 534, 538, 562, 567, 570, 717, 812
absorption of 128
Low physical activity 433
Low-cholesterol diet 209
Low-density lipoprotein 26, 45, 50, 54, 61, 81, 86, 87f, 91, 115, 122, 123, 158, 164, 170, 172, 175, 178, 194, 201, 202, 206, 227, 232, 238, 250, 254, 266, 275, 280, 292, 299, 311, 321, 333, 352, 362, 371, 378, 390, 406, 419, 456, 466, 549, 608, 617, 654, 667, 692, 699, 715, 723, 748, 767, 779, 859, 868, 903, 919
adaptor protein 328
atherogenic 595
drug therapy for elevated 754
lower 573
lowering, targets of 61
particles 164
Low-density lipoprotein cholesterol 4, 10, 18, 31, 31f, 33, 69, 86, 102, 109, 127, 157, 162, 183, 200, 218, 225, 237, 251, 273, 289, 296, 308, 322, 347, 361, 365fc, 369, 369f, 385, 408, 415, 438, 450f, 486, 511, 512t, 547, 554, 583, 597, 626, 660, 691, 734, 753, 759, 780, 794, 804, 835, 855, 859, 866, 882, 900, 901, 914
levels of 14
lowering 108
metabolism of 757
Lower extremity ulceration 493
Lower limb 144
Low-medium intensity statin therapy 498
Low-serum cholesterol 635
Low-wall shear stress 486
Ltraconazole 350
Lumbar spine 220
Lumen 614
Luteinizing hormone 206
Lymphoid cells, proliferation of 810
Lysosomal acid lipase 50
Lysosomes 361
M
Macrolides 812
Malondialdehyde 726
Mast cell activation 786
Matrix metallopeptidase 235
Maximum aortic wall thickness 667
MDGA1 gene 245
Mechanical ventilation 821
Medical therapy 291
Meibomian gland disease 767
Mendelian inherited diseases 338
Menstrual irregularities 204
Mental fitness 138
Mental stress 727
Meta-analysis 911t
Metabolic parameters 228
Metabolic syndrome 11, 13, 18, 20, 58, 67, 73, 86, 110, 146, 149, 169, 179, 209, 225, 239, 284, 290, 291, 406, 418, 555f, 556, 594, 622, 780, 828, 919
prevalence of 10
statin in 556
Methyldopa 713
Methylprednisolone 252
Microembolization, reduction of 345
Microglia 465
Micronutrients 54
Microscopic hematuria 518
Microvascular dysfunction 379
Midazolam 812
Middle east respiratory syndrome 787
Mini gastric bypass 920
Minimal change disease 562
Mitral inflow 632f
Mitral leaflets, anterior and 623f
Mitral stenosis, development of 622
Modulates apoptosis 809
Moens-Korteweg equation 594
Molecular switches 257
Monogenic lipid disorders 338
Mononuclear phagocytes 299
Monounsaturated fat 727
Mucus hypersecretion 786
Multiorgan dysfunction syndrome 821
Multiple focal intense 697f
Multiple lacunar infarcts 465
Multivariate analysis 159
biopsy, indications for 357b
cell
energy production 333
functioning 203
complaints 203
cramps 258
damage markers, role of 357
disease, statin-associated 62
effects, statin-associated 358fc
elevation 263
inflammation 212
injury 355
necrosis 350
pain 268
strength 203
toxicity 105
weakness 258
Mycobacterium tuberculosis 787
MYD88 gene 74
Myeloma, multiple 290
Myeloperoxidases 190
Myocardial apoptosis 420
Myocardial damage, reduction of 344
Myocardial function 654
Myocardial infarction 9, 46, 67, 99, 103, 109, 110, 114, 143, 180, 224, 232, 235, 251, 279, 281, 304, 318, 321, 333, 375, 402, 408, 418, 421, 430, 442, 450, 483, 487, 547, 626, 646f, 712, 733, 757, 794, 855, 857, 858, 867, 887, 906, 910
first 393f
history of 361
Myocardial injury 233
Myocardial mechanics 595
Myocardial performance index 627
Myocardium, actions on 93
Myoglobinuria 350
Myopericarditis 429
Myotoxicity 263
N
Natriuretic peptide, B-type 335
Natural killer activity 810
Nausea 290
Necrotizing autoimmune myopathy, statin-induced 629
Nefazodone 739
Nelfinavir 812
Neoplasms, incidence of 258
Nephrotic dyslipidemia 561
Neurological diseases 221
Neurological disorders, statin in 822
Neurological symptoms 212
Neuropeptide Y 138
Neuropsychiatric effects 258
Neurovascular diseases 820
Neurysmal disease 452
Neutrophils 786
Newer lipid-lowering drugs, classification of 250t
Nicotine 82
Nicotinic acid 749
Niemann-Pick C1-like protein 68
Niemann-Pick protein 127
Nitric oxide 92, 133, 147, 152, 153, 218, 235, 348, 374, 406, 420, 434, 487, 520, 628, 683, 727, 809, 810, 817
activation of 494
availability of 194
deficiency of 178
production 390
reduction in 300
restoring 481
Nitrogen species, reactive 727
No statin therapy 614
Noise 208
risk factors for 164f
Nonantiarrhythmic drugs 433
Noncerebrovascular vessels 493
Noncommunicable diseases 208
Nondiabetes group, risk factors in 474t
Nonenzymatic antioxidants 190
Nonesterified fatty apolipoprotein 544
Nonfasting triglyceride levels 52
Noninvasive imaging techniques 667
Nonlipid 322
Nonmodifiable risk factors 81
Nonpharmacologic interventions 747
Non-ST elevation-acute coronary syndrome 322
Nonstenotic atherosclerotic plaques 116
Nontraditional therapies 749
Nonvitamin K oral anticoagulants 58
Novel emerging therapies 862
Novel therapeutic target 28
Noxious insults 178
Nuclear acids transcription 257
Nutraceuticals 357
Nutritional interventions 224
O
OAS1 gene 245
OAS3 gene 245
Obesity 18, 81, 82, 89, 111, 140, 289, 290, 320, 397, 404, 522, 542, 543f, 553, 594, 622, 716, 717, 752, 755, 780, 828, 918, 921
adipose tissue 542
and metabolic syndrome 919
management, pyramid for 918f
phenomenon of 554
treatment of 224
Ocular surface inflammation 768
Oils, minor components of 728
Oleic acid 728
Open label extension 885
Ophthalmopathy 769
Optic nerve 765
Optic neuropathy, progressive 765
Optimal lipid-lowering therapy 325
Optimal medical treatment 855
Oral hypoglycemic agents 82
Orchestrates development 174
Organ rejection 810
Organ transplantation 233
Organic anion transporter polypeptide 812
ORION-1 trial 900
ORION-3 trial 902
ORION-5 trial 903
Osteoarthritis 553
Osteoblast 220
Osteoclastogenesis 220
Osteoprotegerin 221
Ototoxic drugs 208
Ovariectomy 220
Oxidative phosphorylation 379
Oxidative stress, exercise-induced 726
Oxidized lipoprotein 299
P
Pancreatic lipases 86
Papaverine 684
Paracrine 194
Paraoxonase 816
Parasympathetic nervous system 135
Paresthesias 85
Parkinson's disease 146
Peak atrial systolic strain rate 627
Penile arteries, color Doppler of 683
Penile cavernosal tissue 686
Penile intracavernosal pressure 153
Penile neuronal reflexes 154
Peptide, glucagon-like 58
Percutaneous intervention 887
Percutaneous transluminal coronary angioplasty 232
Perfusion 700fc
Peri-interventional stroke rate 487
Peripheral artery 597
disease 27, 50, 98, 102, 114, 126, 143, 249, 279, 283, 303, 321, 385, 457, 459, 473, 499t, 505, 537, 597, 598, 735, 842, 884, 887, 910
ischemia in 495f
treatment of 499t
Peripheral atherosclerotic disease 497
Peripheral edema 253
Peripheral neuropathy 518
Periprocedural infarction 225
Peroxiredoxins 190
Peroxynitrite 190
Persistent hyperglycemia 573
Persistent hypertension 402
Pharmacogenomic genome 245
Pharmacokinetic genes 242
Phenolic acid 727
Phenotypic components 337
Phentolamine 684
Phenylpiperazine antidepressant 163
Phenytoin 567
Phosphatides 722
Phosphodiesterase 149
Physiological testosterone 153
absorption of 718
biological activities of 718
drug interaction 719
metabolism of 718
nutrient interaction 719
safety of 719
sources of 718
types of 717
Phytosterolemia 719
Pigment stones 172
Placebo 430
Planar xanthomas 780
atheroma 118
calcified 277
characterization 671
components 672t
disruption of 318
formation 834f
grading consensus 658t
high-risk 613
length of 482f
low attenuation 450
mixed 598f
neovascularization 481
paradox 610
passivation 342
concept of 342
regression 324
statin-induced 699
score 658
stable 484
structure 485
thickness 658
visualization of 481
elevation of 81
glucose 716
effects on 188
lipoproteins 333
apheresis 300
low-density lipoprotein cholesterol 891
protein binding 349
protein-A, pregnancy-associated 323
Podocyte injury 564
Polyclonal gammopathy 89
Polygenic dyslipidemias 755
Polygenic hypercholesterolemia, severe 436
Polymeric compounds 224
Polymerization 725
Polymorphism 242
Polyunsaturated fat 727
Polyunsaturated lipids 724
Postablation 431
Postcardioversion 431
Postindex acute coronary syndrome 324
Postmyocardial infarction 5
Post-pacemaker implantation 436
Postprandial lipoprotein metabolism 82
Postrenal transplant, statin in 565
Post-transplantation dyslipidemia, management of 566fc
Potential antifibrinolytic effects 67
Potential anti-inflammatory effects 785f
Pravastatin 26, 39, 44, 45, 72, 73, 74, 104, 105, 108, 123, 128, 144, 157, 173, 180, 181, 185–187, 202, 219, 236, 242, 261, 262, 279, 281, 285, 318, 330, 334, 343, 356, 375, 398, 399, 405, 434, 459, 475, 476, 520, 525, 529, 534, 538, 562, 563, 570, 591, 737, 835, 858
developments of 72
group 296
high-dose 158
treatment 399
Premature atherosclerosis 900
Preocclusion brachial artery 197f
Preproendothelin gene 133
Proatherogenic triglyceride 289
Progesterone 205
Proinflammatory mediators 809
Proinflammatory transcription factors 810
Proliferative vitreoretinal disease 770
Proliferative vitreoretinopathy 770
Proliferative vitreous disease 770
Proprotein convertase subtilisin/kexin 9 6, 12, 22, 25, 30, 32, 33, 35, 39, 49, 68, 98, 115, 176, 215, 250, 251, 266, 292f, 328, 351, 364, 448, 450, 561, 748, 839, 861, 866, 868, 871, 875, 887, 891, 905, 906
biology of 843
gene 249
indications of 49b
monoclonal antibodies 905
protein, drugs targeting 866t
vaccine 48
Proprotein convertase subtilisin/kexin 9 inhibitor 4, 40, 47–49, 68, 98, 117, 240, 293, 300, 339, 351, 361, 362t, 364, 438, 497, 544, 583, 701, 735, 740, 839, 842–844, 861, 868, 868t, 875, 876, 882, 887, 888, 909, 910t, 914
dosing regimens of 867t
pharmacokinetics of 872
pharmacology of 867
plus intensity statin 49
resistance 875
statin and 286
use of 868
with statins 361
Prostaglandins 684
Prostatic hyperplasia, benign 718
Prothrombotic activity 53
Prothrombotic milieu 343
Prothrombotic state 919
Provitamin A 727
Proximal aortopathy 457
P-selectin expression 195
Pulmonary arteries 786
Pulmonary bifurcation, level of 668f
Pulmonary drug toxicity 788
R
Ramipril 652
Rapamycin, mammalian target of 565
Raynaud's phenomena 149
Regeneron 254
Regular aerobic exercise 201
Remnant removal disease 779
Renal complication 458
Renal insufficiency 431
Renal replacement therapy 562
Renal toxicity 259
Reno-aortic ratio 681
Renorenal ratio 680
Reservoir 647
Residual atherogenic dyslipidemia 866
Residual inflammatory risk 58
Resistant plaque burden 340
Respiratory failure, acute 378
Respiratory syndrome coronavirus, severe acute 815
Rest ischemia 496
Rest pain 493
Restoring endothelial function 335
Resveratrol 357
Retinal disease 50
Retinal pathologies 774
Retinal vascular diseases 772
Retinoids 83
Retinol 719
Rheumatic fever, history of 418
Rheumatic heart disease 76
Rho-kinase pathways 178
Rhythm control 429
Richmond agitation sedation scale 822
Rifampicine 567
Rifampin 812
Risperidone 812
Ritonavir 812
Rival statins 126
Rosuvastatin 39, 44, 56, 66, 67, 72–74, 76–79, 93, 102, 105, 108, 116, 123, 128–130, 157, 166f, 186, 187, 191, 202, 206t, 207, 215, 236, 238, 242, 247, 261, 262, 267, 330, 356, 375, 398, 405, 434, 438, 459, 475, 476, 520, 525, 529, 538, 563, 570, 608, 801, 802, 812, 835
combination therapy of 78
effect of 801
high doses of 130
lipid effects of 78
effect of 220
pharmacological characteristics of 76
potency of 128
therapy, effect of 371
tolerability of 79
uptitration 78
use of 129
S
Safety during treatment, monitoring of 11
Scavenger cell receptor 185
Selenoprotein hypothesis 421
Selumetinib 192
Septal mitral annulus tissue Doppler 632f
Serial intravascular ultrasound 740
Serum
alanine aminotransferase 220
aminotransferase 159
amyloid A 179
high 486
nitric oxide 153f
transaminases 803
triglyceride levels 83
Sesamin 727
Sesamolin 727
Shock, cardiogenic 378
Sick fat 918
Sildenafil 153f
Silent strokes 474
Simvastatin 25, 27, 39, 44, 56, 65, 72–74, 93, 104, 105, 108, 123, 126, 128, 157, 163, 170, 173, 185, 187, 191, 202, 205, 207, 214, 236, 242, 261, 262, 269, 368, 375, 398–400, 405, 434, 459, 474–476, 520, 525, 529, 534, 538, 562, 563, 567, 570, 584, 608, 812, 835, 858
attenuates proinflammatory cytokine release 235
high-dose 245
monotherapy group 27
received 98
survival study 648
Single-gene disorders 328
Sitosterol 723
Sleeve gastrectomy 920
Small body frame 233
Small intestine 93
Small vessel ischemia 357
Soft plaque 277
Spinal cord ischemia 458
Spiral ganglion in vitro 210
Spontaneous dissection 116
Spotty calcifications 277
Stable atherosclerotic cardiovascular disease 44
Stanols 717
Staphylococcus aureus 767
Statin 39, 45, 53, 56, 67, 73, 75, 91, 99, 108, 116, 127, 133f, 138, 147, 156, 165, 178, 186, 200, 232, 239, 247, 257, 266, 271, 284, 291, 296, 317, 322, 332, 338, 351, 367, 387, 399, 405, 441, 469, 484, 498, 528, 540, 543, 562, 571, 588, 597, 617, 626, 642, 648, 660, 686, 707, 749, 758, 767, 785, 787, 804, 810, 816, 827, 860, 892f
absorption 128
act 65
after renal transplant 565
after renovascular intervention 505
angiogenesis by 196
anti-inflammatory effects 179
associated muscle symptoms
clinical diagnosis of 356b
mechanism of 355
block production 421
cardiovascular benefits of 529
categorization of 44t
classification of 529t
clinical
dose of 213
trials of 109t
combination 286
therapies 57
comparative efficacy of 262t
contraindications to 239b
discontinuation syndrome 45
drug interactions with 237
effect of 93, 114, 179t, 185b, 218, 219, 243, 299, 303, 304, 322, 324, 356, 398, 434, 438, 486, 496, 670, 672, 677
low-dose 133
elderly and 67
eligibility criteria 272t
era 46
fibrinolytic effect of 196
genetic influences on 244
high potency 259
high-intensity trials on 855
immunomodulatory effects of 810
indications of 248
influence of 399
intensity of 123t
guideline-directed 239
interactions of 439
intervention 266
landmark trials on 737t
legacy effect of 111
less 281
lipid therapy beyond 914
live longer with 183
longer-acting 123
matter, types of 400
monotherapy, use of 409
mortality benefits of 229
myalgia clinical index score 213
properties of 157t
pharmacology 247
pleiotropic
actions of 303b
benefits of 406f
mechanism of 330
properties of 630fc
plus ezetimibe 369
potential
effects of 768f
harm of 421
pleiotropic mechanisms of 809
therapeutic role of 785
pretreatment 487
properties of 186t
protective role of 576
recent trials on 856
regimen 376
response, pharmacogenomics of 242
role of 170, 191f, 201, 204, 204fc, 267, 279, 317, 318, 329, 332–335, 395, 418, 420, 447, 547, 555, 569, 570, 583, 607, 684, 765, 789t, 815
high-dose 105
serum concentrations of 285
story 228
structure of 65
switching 802
target 458
tolerability 529
toxicity 239
trials of 348t
ultimate 238
underutilization of 144
variable properties of 72
Statin and
angiogenesis 132
aortic atherosclerosis 667
arrhythmias 434
arterial stiffness 595
asthma 786
atrial fibrillation 376
bronchiectasis 787
brown adipose tissue 556
cancer 62
cardiovascular events 129
carotid artery
disease 479
intima-media thickness 660
plaque volume 661
plaque vulnerability 661
revascularization 483
stenosis 660
cerebrovascular disease 304
chronic obstructive pulmonary disease 786
cognitive impairment 62
cornea 767
COVID-19 787
endothelial function 195
erectile dysfunction 152
eyes 763
ezetimibe 286
fibrates 286
gallstones disorder 172
gut microflora 555
effect of 554f
heart failure 442
hepatocellular carcinoma 159
hypertension 383
hyperthyroidism 162
idiopathic pulmonary fibrosis 788
incident diabetes risk 540
inflammatory markers 178
kidney 559
lacunar strokes 466
lipid lowering 237
liver
disease 358
enzymes 106
low-density lipoprotein cholesterol control 114
lung infections 787
muscle symptoms 62
new-onset diabetes 62
nonalcoholic steatohepatitis 156
obesity 551
obstructive airway disease 786
ocular surface 767
peripheral vascular disease 305
placebo 372
plaque 371
vulnerability 483
pleiotropic actions 617
pleiotropy 415
proteinuria 220
pulmonary
disorders 785
hypertension 786
restrictive lung diseases 788
retinal disease 770
sepsis 821
in intensive care unit 239
sexual dysfunction 146
skin 777
stroke 62
tuberculosis 787
yoga 827f
Statin in
atherosclerosis, mechanisms of action of 275
diabetes, indications of starting 538
heart failure
effects of 119
hyperthyroidism, role of 162
metabolic syndrome, effects of 555f
obesity, role of 553
plaque
passivation, role of 343
regression, role of 700fc
sepsis, role of 810
stroke prevention, mechanisms of 465
Statin on
angiogenesis, effects of 132
bone, beneficial effects of 221fc
carotid artery atherosclerosis, effect of 590t
coronary artery atherosclerosis, effect of 592t
erectile function, beneficial effects of 152fc
exercise, adverse effects of 203
femoral artery atherosclerosis, effect of 590t
inflammation, effects of 185
lipid profile, effects of 130
liver histology, effects of 165
plaque stability, effects of 185
smooth muscles, effects of 185
vasomotor function, effects of 184
Statin therapy 4, 45t, 58t, 76, 93, 94, 119, 132, 135, 180, 185, 190, 200, 218, 232, 238, 245, 266, 268, 269, 271, 274, 279, 281, 283, 286, 297, 300, 303, 305, 322, 330, 334, 344, 345, 393f, 443, 449t, 457, 471, 475, 475t, 483, 487, 496, 498, 538, 553, 563fc, 584, 595, 597, 599, 600, 613, 626, 633, 657, 679, 683, 758, 843, 866, 878
advances in 67, 247, 320, 328, 351, 374, 385, 390, 429, 433, 436, 456, 465, 468, 473, 481, 486, 493, 496, 527, 542, 547
adverse effects of 471
and osteoporosis 264
before and after 627
benefit of 124
chronic 811
class of 322
classification of 405t
clinical evidence of 343
continuation of 811
controversies of 626
discontinuation of 212
dosage for 104
dual goals for 236
enthusiasm for 230
gender disparity in 261
initiation of 322
intensity of 47
monitoring of 237
nuances of 44
preoperative 374
problems of 296
promise of 833
safety of 345
side effects after 630fc
Stigmasterol 723
Storvastatin 242
acute 136
cardiomyopathy 378
circumferential 343
diastolic 415
myocardial perfusion 692f
proteins 334
psychological 137
role of 138
Stroke 66–68, 81, 91, 99, 135, 137, 232, 269, 282, 284, 299, 347, 402, 457, 458, 465, 474, 481, 518, 794
fatal 283
mouse model of 465
nonfatal 283
pathogenesis of 833
statin in 468
primary prevention 468
rates, effect on 488
recurrent 469
small 466
acute 470
subtype 466
Subclinical cardiovascular disease 149
Subtilisin 32
Sugar 55
Sulfamethoxazole 812
Superoxide dismutase 190
Surgery, types of 920
Switching therapy 214
Sympathetic nervous system 135
Symptomatic gallstone disease 172
Systemic inflammation 379
Systemic inflammatory response syndrome 810
Systolic blood pressure, high 76
Systolic dysfunction 441
Systolic velocity, high 680f
T
T cells, regulatory 179
Tacrolimus 567
Takotsubo cardiomyopathy 378
Takotsubo syndrome, statin therapy in 378
Tendinous xanthomas 780
Terpenoid synthesis 257
Testicular atrophy 153
Tetrahydrobiopterin 180
Therapeutic modalities 20
Therapeutic plasma 176
Thiazolidinediones 82
Thiobarbituric acid reactive substances 726
Thioredoxin 190
Thromboembolic strokes 484
Thrombogenicity 72
Thrombosis 81
Thrombotic complications 311
Thrombotic stroke 468
Thromboxane 93
Thrombus formation 328
Thyrotoxic myopathy 163
Tocilizumab 815
Torasemide 567
Torcetrapib 255
Total atheroma volume 128
Total cardiovascular disease 31f
Total cholesterol 26, 174, 175, 206, 272, 311, 312, 369, 408, 547, 561, 565, 660, 752, 753, 835, 849, 878, 888
higher 204
Toxicity 74
Trans fats 55
Transaminases, increase in 518
Transesophageal ultrasound 667
Transforming growth factor-β 221
Transplant vasculopathy 233
Triacylglycerols 722
Triglyceride 12, 32, 50, 52, 52f, 54, 57, 62, 77, 81, 85, 86, 137, 162, 174, 175f, 206, 244, 247, 250, 254, 290, 293, 294, 312, 408, 433, 438, 450, 547, 456, 566, 716, 724, 734, 752, 753, 835, 883, 920
and fatty acids, metabolism of 88f
concentration 83
drug therapy for elevated 755
enriched lipoprotein 300
hydrolysis of 69
reduction
pharmacological agents on 294
strategies 289
risk 58
role of 452
serum elevations of 919
treatment of high 707
Trimethylamine oxide 828
Triphosphate-citrate lyase 892
Tuberoeruptive xanthomas 780
V
Valve surgery 232
Valvular stenosis 456
Vascular endothelium 97
Vascular end-stage disease, prevention of 398
Vascular events, incidence of 98
Vascular homeostasis 843
Vascular surgeries 820
Vascular system, part of 506
Vasoactive peptides 194
Ventricular fibrillation 421
Ventricular tachyarrhythmias, development of 434
Ventricular tachycardia storm 433
Vertebral artery disease 599
Vessel wall thickness 672
Visual impairment 771
Vitreoretinal disorders, statin in 770
Vomiting 290
Voriconazole 812
Voyager meta-analysis 129